Your browser doesn't support javascript.
loading
VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system.
So, Jonathan; Mabe, Nathaniel W; Englinger, Bernhard; Chow, Kin-Hoe; Moyer, Sydney M; Yerrum, Smitha; Trissal, Maria C; Marques, Joana G; Kwon, Jason J; Shim, Brian; Pal, Sangita; Panditharatna, Eshini; Quinn, Thomas; Schaefer, Daniel A; Jeong, Daeun; Mayhew, David L; Hwang, Justin; Beroukhim, Rameen; Ligon, Keith L; Stegmaier, Kimberly; Filbin, Mariella G; Hahn, William C.
Affiliation
  • So J; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Mabe NW; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Englinger B; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Chow KH; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center and Harvard Medical School, Boston, Massachusetts, USA.
  • Moyer SM; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Yerrum S; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center and Harvard Medical School, Boston, Massachusetts, USA.
  • Trissal MC; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Marques JG; Department of Oncologic Pathology and.
  • Kwon JJ; Center for Patient Derived Models, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Shim B; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Pal S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Panditharatna E; Department of Oncologic Pathology and.
  • Quinn T; Center for Patient Derived Models, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Schaefer DA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Jeong D; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center and Harvard Medical School, Boston, Massachusetts, USA.
  • Mayhew DL; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Hwang J; Department of Pediatric Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorder Center and Harvard Medical School, Boston, Massachusetts, USA.
  • Beroukhim R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Ligon KL; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Stegmaier K; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
  • Filbin MG; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
JCI Insight ; 7(19)2022 10 10.
Article in En | MEDLINE | ID: mdl-36040810
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 4_TD Database: MEDLINE Main subject: Vaccinia / Glioma / Neuroblastoma Type of study: Prognostic_studies Limits: Child / Humans Language: En Journal: JCI Insight Year: 2022 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 4_TD Database: MEDLINE Main subject: Vaccinia / Glioma / Neuroblastoma Type of study: Prognostic_studies Limits: Child / Humans Language: En Journal: JCI Insight Year: 2022 Document type: Article